What is the price-to-earnings ratio of hVIVO?
The price-earnings ratio of hVIVO is currently 1.72.
hVIVO P/S 2025
hVIVO P/S
1.72
Ticker
HVO.L
ISIN
GB00B9275X97
WKN
A1KAME
As of Feb 9, 2025, hVIVO's P/S ratio stood at 1.72, a -40.69% change from the 2.9 P/S ratio recorded in the previous year.
The hVIVO P/S history
hVIVO Aktienanalyse
What does hVIVO do?
Open Orphan PLC is a global company specializing in the development and marketing of therapeutics and vaccines. The company was formed in 2017 through the merger of Venn Life Sciences and Open Orphan Ltd. It was successfully listed on the London Stock Exchange in 2019 and has since expanded and established itself as a major player in the biotechnology industry. Open Orphan's business model is based on collaboration with pharmaceutical and biotech companies to conduct clinical trials and advance the development of therapeutics and vaccines. The company offers innovative and customized solutions tailored to the needs of its clients. Open Orphan operates various divisions, including "Venn Life Sciences," "Clinical Research Services," and "Drug Development Services." These divisions work closely together to conduct a wide range of clinical trials, from Phase I to Phase IV studies. The company specializes in conducting clinical trials for rare diseases such as congenital heart failure or rare neurological disorders. It also conducts studies in the field of infectious diseases, such as COVID-19. In addition to its role as a Contract Research Organization (CRO), Open Orphan also offers its own products. This includes the "COVID-19 Human Challenge Trial" program, which involves intentionally infecting volunteers with the coronavirus to test the efficacy of vaccines and therapeutics. Another product offered by Open Orphan is the "Venus Flu Study," a clinical trial for a novel flu vaccine. Open Orphan also operates its own platform called the "Orphan Drug Accelerator," an online marketplace specializing in accelerating the market launch of orphan drugs. Biotech companies, investors, and regulatory authorities can connect and collaborate on this platform to expedite the development and marketing of orphan drugs. Overall, Open Orphan is an emerging company in the biotechnology industry, specializing in conducting clinical trials and developing and marketing therapeutics and vaccines. With its innovative and tailored solutions, as well as its own products, the company has already attracted a variety of customers and investors. hVIVO ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding hVIVO's P/S Ratio
hVIVO's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing hVIVO's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating hVIVO's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in hVIVO’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about hVIVO stock
How has the price-earnings ratio of hVIVO changed compared to last year?
The price-to-earnings ratio of hVIVO has increased by -40.69% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of hVIVO high compared to other companies?
Yes, the price-to-earnings ratio of hVIVO is high compared to other companies.
How does an increase in the price-earnings ratio of hVIVO affect the company?
An increase in the price-earnings ratio of hVIVO would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of hVIVO affect the company?
A decrease in the price-earnings ratio of hVIVO would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of hVIVO?
Some factors that influence the price-earnings ratio of hVIVO are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does hVIVO pay?
Over the past 12 months, hVIVO paid a dividend of 0 GBP . This corresponds to a dividend yield of about 2.57 %. For the coming 12 months, hVIVO is expected to pay a dividend of 0 GBP.
What is the dividend yield of hVIVO?
The current dividend yield of hVIVO is 2.57 %.
When does hVIVO pay dividends?
hVIVO pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of hVIVO?
hVIVO paid dividends every year for the past 0 years.
What is the dividend of hVIVO?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 1.14 %.
In which sector is hVIVO located?
hVIVO is assigned to the 'Health' sector.
Wann musste ich die Aktien von hVIVO kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of hVIVO from 5/20/2024 amounting to 0.002 GBP, you needed to have the stock in your portfolio before the ex-date on 4/18/2024.
When did hVIVO pay the last dividend?
The last dividend was paid out on 5/20/2024.
What was the dividend of hVIVO in the year 2024?
In the year 2024, hVIVO distributed 0.005 GBP as dividends.
In which currency does hVIVO pay out the dividend?
The dividends of hVIVO are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von hVIVO
Our stock analysis for hVIVO Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of hVIVO Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.